Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial. // International Journal of Gynecological Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1048891X26004780?dgcid=rss_sd_all
Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial. International Journal of Gynecological Cancer. https://www.sciencedirect.com/science/article/pii/S1048891X26004780?dgcid=rss_sd_all
“Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.” International Journal of Gynecological Cancer.
@article{article118799,
title = {Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial},
journal = {International Journal of Gynecological Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1048891X26004780?dgcid=rss_sd_all}
}